EGFR and lung adenocarcinoma: In the era of molecular and personalized therapeutics, the discovery of mutations in EGFR in 15-20% of lung adenocarcinomas and the associated response to EGFR-targeting tyrosine kinase inhibitors have provided a successful avenue of treatment in high-stage lung adenocarcinomas.